Monte Rosa Therapeutics, Inc. (GLUE)
10.30
-0.02
(-0.19%)
USD |
NASDAQ |
Oct 09, 16:00
10.30
0.00 (0.00%)
After-Hours: 20:00
Monte Rosa Therapeutics Net Income (Quarterly) : -43.40M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -43.40M |
| March 31, 2026 | -44.50M |
| December 31, 2025 | -46.14M |
| September 30, 2025 | -27.08M |
| June 30, 2025 | -12.30M |
| March 31, 2025 | 46.88M |
| December 31, 2024 | 13.44M |
| September 30, 2024 | -23.86M |
| June 30, 2024 | -30.31M |
| March 31, 2024 | -31.97M |
| December 31, 2023 | -33.25M |
| September 30, 2023 | -34.88M |
| June 30, 2023 | -35.18M |
| Date | Value |
|---|---|
| March 31, 2023 | -32.04M |
| December 31, 2022 | -30.78M |
| September 30, 2022 | -27.32M |
| June 30, 2022 | -26.47M |
| March 31, 2022 | -23.93M |
| December 31, 2021 | -23.44M |
| September 30, 2021 | -19.84M |
| June 30, 2021 | -18.40M |
| March 31, 2021 | -12.28M |
| December 31, 2020 | -19.66M |
| September 30, 2020 | -6.558M |
| June 30, 2020 | -5.364M |
| March 31, 2020 | -4.302M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| United Therapeutics Corp. | 333.00M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 8.968M |
| Total Expenses (Quarterly) | 52.36M |
| EPS Diluted (Quarterly) | -0.4276 |
| Enterprise Value | 294.71M |
| Gross Profit Margin (Quarterly) | 78.69% |
| Profit Margin (Quarterly) | -483.9% |
| Earnings Yield | -18.50% |
| Normalized Earnings Yield | -18.50 |